Abstract | BACKGROUND: Pancreatic exocrine insufficiency is a common condition in patients with cystic fibrosis. Large amounts of pancreatic enzyme supplements are required to reduce malabsorption but patient compliance is not always optimal. AIMS: PATIENTS: METHODS: Patients were assigned to the crossover treatment with Creon or Pancrease for 1 week and then to the alternative treatment. Patients had to follow a fixed diet (at least 2 g fat/kg) and had to assume 1000 units lipase/g fat. The evaluation parameters were: patients' preference, acceptance of therapy, stool fat excretion, stool weight, gastrointestinal symptoms, and tolerance. RESULTS AND CONCLUSIONS: Of the 33/60 patients who expressed a preference for one of the two treatments, 30 preferred Creon while only 3 patients preferred Pancrease (p<0.001). No difference between the two treatments was observed regarding stool characteristics, gastrointestinal symptoms and tolerance. The mean number of capsules taken daily was reduced by 35% with Creon. The results of this study showed a preference in favour of Creon probably due to the reduction of daily capsule intake of 35%, supporting digestion as well as Pancrease.
|
Authors | B Santini, M Antonelli, A Battistini, S Bertasi, M Collura, I Esposito, L Di Febbraro, R Ferrari, L Ferrero, L Iapichino, V Lucidi, A Manca, C L Pisconti, G Pisi, V Raia, L Romano, P Rosati, I Grazioli, G Melzi |
Journal | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
(Dig Liver Dis)
2000 Jun-Jul
Vol. 32
Issue 5
Pg. 406-11
ISSN: 1590-8658 [Print] Netherlands |
PMID | 11030186
(Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article)
|
Chemical References |
- Capsules
- Gastrointestinal Agents
- Pancrelipase
- Lipase
- Amylases
- Endopeptidases
|
Topics |
- Adolescent
- Adult
- Amylases
(administration & dosage)
- Capsules
- Child
- Cystic Fibrosis
(complications)
- Drug Tolerance
- Endopeptidases
(administration & dosage)
- Exocrine Pancreatic Insufficiency
(drug therapy, etiology)
- Female
- Gastrointestinal Agents
(administration & dosage)
- Humans
- Lipase
(administration & dosage)
- Male
- Microspheres
- Pancrelipase
(administration & dosage)
- Patient Acceptance of Health Care
- Safety
|